29:I[164923,["/_next/static/immutable/chunks/0x-9rc1bm-510.js","/_next/static/immutable/chunks/0u73ovrok9bmr.js","/_next/static/immutable/chunks/3t9ifrnugpnlb.js","/_next/static/immutable/chunks/3gdp0tzp2t65u.js","/_next/static/immutable/chunks/0qexc5596g7lf.js","/_next/static/immutable/chunks/3nkl8euu6dycn.js","/_next/static/immutable/chunks/28p3k9kvs3dfa.js","/_next/static/immutable/chunks/04j_o97cgxn2x.js","/_next/static/immutable/chunks/18bybpoq919w1.js"],"ClinicalTrialDetail"] 25:["$","script","1",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Clinical Trials\",\"item\":\"https://clareohealth.com/clinical-trials\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acute Myelogenous Leukemia\",\"item\":\"https://clareohealth.com/clinical-trials/condition/acute-myelogenous-leukemia\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"NCT07566377\",\"item\":\"https://clareohealth.com/clinical-trials/NCT07566377\"}]}"}}] 26:["$","script","2",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"MedicalWebPage\",\"name\":\"Cord Blood Transplantation in Children and Young Adults With Blood Cancer\",\"description\":\"The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.\",\"url\":\"https://clareohealth.com/clinical-trials/NCT07566377\",\"mainEntity\":{\"@id\":\"https://clareohealth.com/clinical-trials/NCT07566377\"},\"specialty\":{\"@type\":\"MedicalSpecialty\",\"name\":\"Clinical Research\"},\"audience\":{\"@type\":\"PeopleAudience\",\"audienceType\":\"Patients and Caregivers\"},\"lastReviewed\":\"2026-05-14\",\"medicalAudience\":{\"@type\":\"MedicalAudience\",\"audienceType\":\"Patient\"},\"reviewedBy\":{\"@type\":\"Organization\",\"name\":\"ClinicalTrials.gov\",\"url\":\"https://clinicaltrials.gov\"}}"}}] 2a:T1f3a,Inclusion Criteria: A patient cannot be considered eligible for this study unless ALL of the following conditions are met. ° Disease type Cohort 1, High Risk Disease: Patients with age ≤ 26 years at the time of informed consent with no available and suitably matched related or unrelated donor within 4 weeks, with one of the following diagnoses: I. Acute myelogenous leukemia (AML): * Complete first remission (CR1) with blast count \< 5% by bone marrow morphology at high risk for relapse such as any of the following: * Known prior diagnosis of myelodysplasia (MDS) * High risk cytogenetics (e.g., those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) and/or high-risk molecular abnormalities (e.g., TP53) * Requirement for 2 or more inductions to achieve CR1 * Therapy-related AML (t-AML) or therapy-related myeloid neoplasm (t-MN) (including after therapy for other malignancy, and/or gene therapy or cell therapy) * Presence of Minimal/Measurable Residual Disease (MRD+) by cytogenetics, flow cytometry or molecular methods (at End of Induction or End of Consolidation) * Other high-risk features not defined above. * Complete second remission (CR2) or subsequent remission, with blast count \< 5% by bone marrow morphology * Presence of MRD by multiparameter flow cytometry at pre-transplant evaluation is acceptable. II. Acute lymphoblastic leukemia (ALL): * Complete first remission (CR1) with MRD negative status by multicolor flow cytometry, at high risk for relapse such as any of the following: * Presence of any high risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other, KMT2A (11q23) or other high risk molecular abnormality * Failure to achieve complete remission (CR) after four weeks of induction therapy (transplant to follow antibody therapy and/or CAR T cells) * Persistence or recurrence of MRD on therapy (Transplant to follow antibody therapy and/or CAR T cells) * T-ALL in CR even with presence of MRD * Other high-risk features not defined above * Complete second remission (CR2) or subsequent remission with MRD negative status by multiparameter flow cytometry. * Relapse in less than 36 months from CR1 * Relapse for T-ALL * Patients after antibody therapy (e.g., blinatumomab, inotuzumab, other) and/or CAR-T cell therapy that resulted in MRD negative status by multiparameter flow cytometry. III. Other acute leukemias: * Leukemias of ambiguous lineage or of other types with \< 5% blasts by bone marrow morphology. * Patients with persistent/relapsed disease with cytogenetic, flow cytometric or molecular aberrations in \< 5% of cells. * Chronic myelogenous leukemia: Patients with history of blast crisis or accelerated phase. * Any leukemia that developed after gene therapy or cell therapy IV. Myelodysplastic Syndrome (MDS): * Any IPSS risk category with life-threatening cytopenia(s). * Any IPSS risk category with high risk cytogenetic/molecular findings (5, 7, 8, complex karyotype, or TP53) V. Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high risk of relapse or progression if not in remission: * Patients with aggressive histology (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell NHL) in CR. * Patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with stable disease/ CR/ PR with no single lesion equal to or more than 5 cm. * Patients with HL without progression of disease (POD) after salvage chemotherapy with no single lesion ≥5 cm. Cohort 2: Very High-Risk disease: 1. Patients in CR (bone marrow blasts \<5% by morphology) who had prior allogeneic transplant and disease recurrence. The second transplant will take place at least 4 months after the first. * Acute myelogenous leukemia (AML) or Myelodysplastic Syndrome (MDS): Relapse after previous transplant, in CR after induction therapy. MRD positive status by multi-parameter flow cytometry is accepted. * Acute lymphoblastic leukemia (ALL): Relapse after previous transplant, in CR after induction therapy and/or antibody therapy/CAR T cells. MRD positive status after targeted therapy, as evaluated by multi-parameter flow cytometry is accepted. * Other: patients with leukemia or lymphoma, who, in the opinion of their physician, are not likely to have reduction in disease burden with further chemotherapy. 2. Patients with relapsed/refractory disease at either first or second allogeneic transplant, with up to 30% bone marrow blasts by multiparameter flow cytometry or morphology. ° Relapse after previous transplant with \< 30% blasts by bone marrow morphology, or with cytogenetic, flow cytometric, or molecular abnormalities in \< 30% of bone marrow cells, after induction therapy. ° Primary refractory or relapsed AML with \< 30% blasts by bone marrow morphology or with cytogenetic, flow cytometric, or molecular abnormalities in \< 30% of bone marrow cells. ° Age 0-26 years at the time of informed consent ° Performance: Karnofsky (≥16 years) or Lansky score (\<16 years) of ≥70% (see Appendix A). ° Not Pregnant and Not Nursing ° Required Organ Function * Bilirubin ≤ 1.5 mg/dL (unless benign congenital hyperbilirubinemia). * ALT ≤ 3 x upper limit of normal. * Pulmonary function (FVC, FEV1 and DLCO corrected for hemoglobin) ≥ 50% predicted. * In young children unable to perform pulmonary function testing: pulse oximetry \>92% in room air, and a normal CT of the chest (if CT is not normal, the child needs to be evaluated and cleared by pediatric pulmonary physician). * Left ventricular ejection fraction \> 50%. * Age-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) ≤ 7. * Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of enrolment and must be willing to use an effective contraceptive method while enrolled in the study. * Renal: Serum creatinine (SCr) ≤ 1.5 x normal for age. If SCr is outside the normal range, then CrCl \> 50 mL/min (calculated or estimated) or estimated GFR (mL/min/1.73m2) \>30% of predicted normal for age. Normal GFR by Age : Mean GFR +- SD (mL/min/1.73m\^2) 1 week : 40.6 + / - 14.8 2-8 weeks : 65.8 + / - 24.8 \>8 weeks : 95.7 + / - 21.7 2-12 years : 133.0 + / - 27.0 13-21 years (males) : 140.0 + / - 30.0 13-21 years (females) : 126.0 + / - 22.0 GFR, glomerular filtration rate; SD, standard deviation; Greater than 2 years old: Normal GFR is 100 mL/ min; Infants: GFR must be corrected for body surface area. Exclusion Criteria: Exclusion criteria for both cohorts: ° Inadequate performance status/ organ function. ° Active CNS leukemic involvement. * Chloroma \>2 cm. * Active and uncontrolled infection (bacterial/fungal/viral) at time of transplant. * HIV infection. * Seropositivity for HTLV-1. * Pregnancy or breast feeding. * Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests. * Any abnormal condition or lab result that is considered by the PI capable or altering patient's condition or study outcome. Cohort 2 Very High-Risk Disease (additional to above): ° Allogeneic HCT in the preceding 4 months. Note (1): Prior checkpoint inhibitors/blockade in the last 12 months: eligibility to be discussed with study PI. Note (2): For patients with known HBV and/or HCV infection : * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.27:["$","$L29",null,{"trial":{"nctId":"NCT07566377","briefTitle":"Cord Blood Transplantation in Children and Young Adults With Blood Cancer","officialTitle":"Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies","briefSummary":"The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.","detailedDescription":null,"overallStatus":"RECRUITING","phase":"PHASE2","studyType":"INTERVENTIONAL","conditions":["Acute Myelogenous Leukemia","Acute Lymphoblastic Leukemia","Myelodysplastic Syndromes","Non-hodgkin Lymphoma","Hodgkin Lymphoma","Leukemia","Lymphoma","Graft-versus-host Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Cord Blood Units","description":"Cord Blood \\[(HPC(CB)\\] products are minimally manipulated unrelated allogeneic cord blood units that have been collected, processed and stored in public Cord Blood banks"},{"type":"RADIATION","name":"Total Body Irradiation","description":"Hyper-fractionated TBI is administered by a linear accelerator at a dose rate of \\<20 cGy/minute. Treatment planning begins with simulation."},{"type":"DRUG","name":"Cyclophosphamide","description":"Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis."},{"type":"DRUG","name":"Fludarabine","description":"Fludarabine phosphate is rapidly dephosphorylated to 2- fluoro-ara- A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2- fluoro-ara-ATP"},{"type":"DRUG","name":"Clofarabine","description":"Clofarabine, a purine (deoxyadenosine) nucleoside analog, is metabolized to clofarabine 5'-triphosphate."},{"type":"DRUG","name":"Busulfan","description":"Busulfan is a bifunctional alkylating agent known chemically as 1,4- butanediol, dimethanesulfonate."},{"type":"DRUG","name":"Thiotepa","description":"Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent."},{"type":"DRUG","name":"Tacrolimus","description":"Tacrolimus inhibits T-lymphocyte activation"},{"type":"DRUG","name":"Mycophenolate Mofetil","description":"Mycophenolate exhibits a cytostatic effect on T and B lymphocytes."},{"type":"DRUG","name":"Cyclosporine","description":"Cyclosporine is a calcineurin inhibitor that inhibits production and release of interleukin II and inhibits interleukin II-induced activation of resting T-lymphocytes."}],"keywords":["Cord blood transplants","Graft-versus-host Disease","Lymphoma","Leukemia","Hodgkin Lymphoma","Non-hodgkin Lymphoma","Myelodysplastic Syndromes","Acute Lymphoblastic Leukemia","Acute Myelogenous Leukemia","Memorial Sloan Kettering Cancer Center","26-168"],"locations":[{"facility":"Memorial Sloan Kettering Cancer Center (All Protocol Activities)","city":"New York","state":"New York","country":"United States","zip":"10065","lat":40.71427,"lng":-74.00597}],"eligibilityCriteria":"$2a","minAge":null,"maxAge":26,"sex":"ALL","healthyVolunteers":false,"leadSponsor":"Memorial Sloan Kettering Cancer Center","collaborators":null,"contacts":[{"name":"Andromachi Scaradavou, MD","role":"CONTACT","phone":"833-MSK-KIDS","email":"ScaradaA@mskcc.org"},{"name":"Jaap Jan Boelens, MD, PhD","role":"CONTACT","phone":"833-MSK-KIDS","email":"boelensj@mskcc.org"}],"startDate":"$D2026-04-28T00:00:00.000Z","completionDate":"$D2030-04-28T00:00:00.000Z","primaryCompletionDate":"$D2030-04-28T00:00:00.000Z","firstPostDate":"$D2026-05-05T00:00:00.000Z","lastUpdatePostDate":"$D2026-05-14T00:00:00.000Z","enrollmentCount":71,"enrollmentType":"ESTIMATED","aiSummary":"$undefined","aiSummaryGeneratedAt":null,"id":"$undefined","createdAt":"$undefined","updatedAt":"$undefined"}}]

What this study is about